These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 34724173)

  • 1. The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density.
    van der Burgh AC; de Keyser CE; Zillikens MC; Stricker BH
    Drugs; 2021 Nov; 81(16):1831-1858. PubMed ID: 34724173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
    Levis S; Theodore G
    J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The biology of fracture healing in osteoporosis and in the presence of anti-osteoporotic drugs.
    Hak DJ
    Injury; 2018 Aug; 49(8):1461-1465. PubMed ID: 29709376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of osteoporosis medications on fracture healing.
    Hegde V; Jo JE; Andreopoulou P; Lane JM
    Osteoporos Int; 2016 Mar; 27(3):861-871. PubMed ID: 26419471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk.
    Nayak S; Greenspan SL
    Osteoporos Int; 2019 Apr; 30(4):705-720. PubMed ID: 30623214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic Effects of the Third Generation Bisphosphonate of Risedronate on Rat Osteoporotic Fractures for Clinical Usage Guidance.
    Ke CH; Li HY; Yang D; Ying H; Xu J; Wang J; Zhu HW; Wang L
    Orthop Surg; 2021 Dec; 13(8):2433-2441. PubMed ID: 34676672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone Mineral Density Loss and Fracture Risk After Discontinuation of Anti-osteoporotic Drug Treatment: A Narrative Review.
    Elbers LPB; Raterman HG; Lems WF
    Drugs; 2021 Sep; 81(14):1645-1655. PubMed ID: 34524681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New therapeutic targets for osteoporosis.
    Anagnostis P; Gkekas NK; Potoupnis M; Kenanidis E; Tsiridis E; Goulis DG
    Maturitas; 2019 Feb; 120():1-6. PubMed ID: 30583758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative bone health assessment and optimization in spine surgery.
    Anderson PA; Kadri A; Hare KJ; Binkley N
    Neurosurg Focus; 2020 Aug; 49(2):E2. PubMed ID: 32738805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Theoretical consideration of the effect of drug holidays on BMD and tissue age.
    Hernandez CJ; Lopez HK; Lane JM
    Osteoporos Int; 2014 May; 25(5):1577-84. PubMed ID: 24570296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture.
    Ferrari S; Reginster JY; Brandi ML; Kanis JA; Devogelaer JP; Kaufman JM; Féron JM; Kurth A; Rizzoli R
    Arch Osteoporos; 2016 Dec; 11(1):37. PubMed ID: 27800591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Trabecular Bone Score (TBS) as a Complementary Approach to Dual-energy X-ray Absorptiometry (DXA) for Fracture Risk Assessment in Clinical Practice.
    Shevroja E; Lamy O; Kohlmeier L; Koromani F; Rivadeneira F; Hans D
    J Clin Densitom; 2017; 20(3):334-345. PubMed ID: 28734710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subjects with osteoporosis to remain at high risk for fracture despite benefit of prior bisphosphonate treatment-a Danish case-control study.
    Hansen L; Petersen KD; Eriksen SA; Gerstoft F; Vestergaard P
    Osteoporos Int; 2017 Jan; 28(1):321-328. PubMed ID: 27475930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.
    Bover J; Bailone L; López-Báez V; Benito S; Ciceri P; Galassi A; Cozzolino M
    J Nephrol; 2017 Oct; 30(5):677-687. PubMed ID: 28432640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures.
    Poon Y; Pechlivanoglou P; Alibhai SMH; Naimark D; Hoch JS; Papadimitropoulos E; Hogan ME; Krahn M
    BJU Int; 2018 Jan; 121(1):17-28. PubMed ID: 28921820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of anti-osteoporotic medications in patients with type 1 and 2 diabetes mellitus: a systematic review.
    Anagnostis P; Paschou SA; Gkekas NN; Artzouchaltzi AM; Christou K; Stogiannou D; Vryonidou A; Potoupnis M; Goulis DG
    Endocrine; 2018 Jun; 60(3):373-383. PubMed ID: 29411304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.
    Bell JM; Shields MD; Watters J; Hamilton A; Beringer T; Elliott M; Quinlivan R; Tirupathi S; Blackwood B
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010899. PubMed ID: 28117876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.